PTEN/MMAC1 mutations correlate inversely with an altered p53 tumor suppressor gene in gynecologic tumors

American Journal of Obstetrics and Gynecology

Volumn 188, Issue 4, 2003, Pages

  Soyoola, Emmanuel O ^a   Pattillo, Roland A ^a  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

African American cancer survival; Endometrial cancer; MMAC mutation; P53 mutation; PTEN mutation; Tumor suppressor gene

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PHOSPHATASE; PTEN PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

BINDING SITE; CHINESE; CLINICAL ARTICLE; CODON; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA BINDING; ENDOMETRIUM CARCINOMA; FEMALE; FEMALE GENITAL TRACT TUMOR; GEL ELECTROPHORESIS; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; MOLECULAR GENETICS; NEGRO; PRIORITY JOURNAL; RACE DIFFERENCE; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE; ARTICLE; ASIAN; GENETICS; MUTATION; NUCLEOTIDE SEQUENCE;

AFRICAN CONTINENTAL ANCESTRY GROUP; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; CODON; FEMALE; GENE FREQUENCY; GENITAL NEOPLASMS, FEMALE; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PHOSPHORIC MONOESTER HYDROLASES; POLYMORPHISM, GENETIC; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0346307523     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2003.243     Document Type: Conference Paper

References (14)

1. Clifford SL, Kaminetsky CP, Frank D, Dodge R, Soper JT, Clarke-Pearson DL, et al. Racial disparity in overexpression of p53 tumor suppressor gave in stage I endometrial cancer. Am J Obstet Gynecol 1997;176:S229-32.
2. Miller BA, Ries LAG, Hankey BF, Kosar CL, Harras A, Devesa SS, et al, editors. SEER cancer statistics review: 1973-1990. Bethesda, MD: National Cancer Institute; 1993. NIH publication 93-2789.
3. Kohler MF, Carney P, Dodge R, Soper JT, Clarke-Pearson DL, Marks JR, et al. p53 overexpression in advanced-stage endometrial adenocracinoma. Am J Obstet Gynecol 1996;175:1246-52.
4. Schottenfeld D. Determinants of black/white survival differences among women with endometrial cancer. Gynecol Oncol 1995;56:151-3.
5. Bain RP, Greenberg RS, Chung KC. Racial differences in survival of women with endometrial cancer. Am J Obstet Gvnecol 1987;157:914-23.
6. Berchuck A, Boyd J. Molecular basis of endometrial cancer. Cancer 1995;76:2034-40.
7. Berchuck A, Kohler MF, Marks JR. The p53 tumor suppressor gene is frequently altered in gynecologic cancer. Am J Obstet Gynecol 1994;170:246-52.
8. Ito K, Watanabe K, Nasim S, Sasano H, Sato S, Yajima A, et al. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res 1994;4667-70.
9. Ferencry A, Franco E. Persistent human papilloma virus infection and cervical neoplasia. Lancet Oncol 2002;3:11-6.
10. Sisk EA, Robertson ES. Clinical implications of human papilloma virus infection. Front Biosci 2002;7:e77-84.
11. Kigawa J, Sato S, Shimada M, Takahashi M, Itamochi H, Kanamori Y, et al. p53 gene status and chemosensitivity in ovarian cancer. Cell 2001;14:165-71.
12. Steck P, Pershouse M, Jasser S, Yung W, Lin H, Ligon A, et al. Identification of a candidate tumor suppressor gene, MMAC 1 at chromose 10q, 23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356-62.
13. Risinge J, Hayes K, Maxwell G, Carney M, Dodge R, Barrett C, et al. PTEN mutation in endometrial cancer is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 1998;4:3005-10.
14. Kim HJ, Song, ES, Hwang TS. Higher incidence of p53 mutation in cervical carcinomas with intermediate-risk HPV infection. Eur J Obstet Gynecol Reprod Biol 2001;98:213-8.